Systematic Literature Reviews for Health Technology Assessment and Market Access: A Complete Guide
A systematic literature review for health technology assessment (HTA) is a payer-focused, protocol-driven evidence synthesis that identifies, appraises, and summarizes clinical, economic, and humanistic studies to support reimbursement decisions. It differs from an academic review in audience, PICOS rigor, and timelines. This guide explains how these reviews work and the standards that govern them.
Dr. Kwame Asante
July 9, 2026
Key Takeaways
An HTA systematic literature review is a payer-focused, protocol-driven synthesis, not an academic exercise.
PICOS scoping and comparator completeness decide whether a submission survives agency critique.
HTA reviews run in three strands: clinical, economic, and humanistic, together forming the HEOR evidence base.
Searches span clinical and economic databases plus grey literature, documented to reproducible syntax.
AMSTAR 2 appraises existing reviews while RoB 2 and ROBINS-I appraise individual studies.
Indirect treatment comparison and network meta-analysis fill the gap when head-to-head trials are missing.
The review feeds a global value dossier or AMCP dossier and must report to PRISMA standards.
What a Systematic Literature Review Means in Health Technology Assessment
A systematic literature review (SLR) in the context of health technology assessment (HTA) is a transparent, protocol-driven synthesis of all relevant clinical, economic, and quality-of-life evidence assembled to inform reimbursement and pricing decisions. Unlike a general academic review that aims to answer a scientific question, an HTA-oriented SLR is built to satisfy payers, HTA agencies, and regulators who decide whether a therapy delivers enough value to justify public or insurer funding. The output feeds submissions to bodies such as NICE, CADTH, and ICER, and it underpins the evidence sections of pricing and reimbursement dossiers.
Health technology assessment is the multidisciplinary evaluation of a drug, device, diagnostic, or procedure across clinical effectiveness, cost effectiveness, and broader social value. Because these assessments carry direct budget consequences, the evidence base cannot be assembled selectively or informally. A rigorous systematic literature review provides the defensible, reproducible foundation that a payer will scrutinize closely. This guide explains how these reviews are scoped, conducted, appraised, and reported, and how they differ from the reviews familiar to academic researchers. If you need a review executed to submission standard, our team offers our HTA and market access review service, but the goal here is to teach the method.
How an HTA Review Differs From an Academic Systematic Review
The methods share a common backbone, yet the purpose reshapes almost every decision. An academic systematic review is written for peer reviewers and the scientific community, and it privileges internal validity and knowledge generation. An HTA review is written for a payer, a reimbursement committee, or a regulator, and it privileges decision relevance, comparator completeness, and auditability.
Frequently Asked Questions
8
Both share the same core methods, but an HTA review is built for payers and reimbursement agencies rather than for peer reviewers. It applies PICOS with unusual precision, prioritizes comparator completeness and decision relevance, captures economic and humanistic evidence alongside efficacy, and is engineered around fixed regulatory deadlines. It must also be fully reproducible so that an agency can re-run and challenge the search during its critique.
The most frequently referenced agencies are NICE in England and Wales, CADTH in Canada, ICER in the United States, and G-BA with its scientific institute IQWiG in Germany. Others include France's HAS and Australia's PBAC. Each publishes its own methods guidance and comparator expectations, so a single evidence base often has to be adapted into several country-specific submissions.
HTA evidence packages usually combine a clinical review of efficacy and safety, an economic review of cost-effectiveness and resource-use studies, and a humanistic review of quality-of-life and patient-reported outcome evidence. Each has its own protocol, databases, and appraisal tools, and together they represent the broader field of health economics and outcomes research.
PICOS defines the population, intervention, comparators, outcomes, and study design that scope the review. In HTA the comparator element is decisive, because agencies such as NICE and G-BA will reject an evidence base that omits a therapy they regard as standard of care. A precise, documented PICOS specification prevents costly rework when an agency challenges the decision problem.
AMSTAR 2 is a validated sixteen-item instrument for appraising the methodological quality of existing systematic reviews. It flags critical weaknesses such as a missing protocol, an incomplete search, or a failure to account for risk of bias in the included studies. In HTA it helps a team decide how much confidence to place in previously published reviews before relying on them as evidence.
They are needed when direct head-to-head trials between a new therapy and every relevant comparator do not exist, which is common in market access. An indirect treatment comparison estimates relative effects through a common comparator, while a network meta-analysis synthesizes a connected network of trials simultaneously. Both rely on assumptions about trial similarity that must be examined and reported transparently.
The review supplies the evidence tables, comparator effect estimates, and appraisal that give a global value dossier or an AMCP dossier their authority. The dossier consolidates clinical, economic, and humanistic evidence into a single narrative that local teams adapt into country-specific submissions. Because dossiers are updated as new trials read out, the underlying reviews are usually designed to be refreshed efficiently.
A full systematic review applies the complete comprehensive process across all relevant databases and is expected for major national HTA submissions where completeness must be demonstrated. A targeted or focused review narrows the databases, date range, comparators, or outcomes to answer a specific question faster. Any narrowing of scope must be stated explicitly so readers understand the limits of the conclusions.
Share
Found this useful? Share it with your colleagues.
Need help with your evidence synthesis?
Our methodologists handle narrative synthesis, thematic analysis, umbrella reviews, and all forms of evidence synthesis, following established frameworks.
Complex Synthesis? Our PhD Team Specializes in Every Type.
Systematic reviews, narrative synthesis, umbrella reviews, and rapid reviews. We match the right methodology to your research question and deliver a publication-ready manuscript.
Our promise: Free rework on synthesis or GRADE assessment if reviewers push back.
4.9 / 5Quote in minutesPRISMA 2020 + GRADE certaintyPhD methodologistNDA available on request
PhD in Health Systems Research. Your named contact from kick-off to delivery on institutional, multi-site, and grant-funded engagements. Owns scope, milestones, and turnaround on every engagement.
Complex Synthesis? Our PhD Team Specializes in Every Type.
Systematic reviews, narrative synthesis, umbrella reviews, and rapid reviews. We match the right methodology to your research question and deliver a publication-ready manuscript.
Quote in minutes. Pay only after you approve your quote. Unlimited revisions until your reviewers are satisfied. NDA available on request.
Several practical differences stand out. First, the scope is dictated by the specific decision problem rather than by scientific curiosity, so the PICOS framework is applied with unusual precision and often mirrors the exact population and comparators an HTA agency has already defined. Second, the review is deadline-driven; a submission window to a national agency will not move, so the process is engineered around fixed regulatory timelines. Third, an HTA review must capture not only efficacy but also cost, resource use, and patient-reported outcomes, because a reimbursement case rests on value rather than clinical benefit alone. Fourth, the review must be reproducible to an external auditor, since agencies routinely re-run or challenge searches during their critique. These pressures make the discipline of market access evidence synthesis distinct from academic practice, even when the underlying screening and extraction steps look familiar. Teams that also produce conventional academic reviews through our systematic review services will recognize the shared machinery, but the acceptance criteria here are set by reimbursement stakeholders.
The HTA Bodies That Set the Standards
Understanding the audience is essential because each agency publishes methods guidance that shapes how an SLR must be built. NICE in England and Wales evaluates technologies through its technology appraisal and health technology evaluation programs and expects a comprehensive review of clinical and economic evidence, often with a fully documented search strategy and a critique-ready reference pack. CADTH in Canada performs reimbursement reviews for drugs and devices and applies detailed procedural expectations for search transparency and comparator justification. In the United States, ICER conducts independent value assessments that combine a clinical review with a cost-effectiveness model and a budget-impact analysis, and its reports are widely referenced by payers.
Beyond these three, Germany's Federal Joint Committee, known as G-BA, and its scientific institute IQWiG operate an early benefit assessment that is notably strict about the appropriate comparator therapy and the hierarchy of endpoints. Other jurisdictions, including France's HAS and Australia's PBAC, add their own requirements. The common thread is that a single global evidence base often has to be adapted into multiple country-specific submissions, each with its own comparators and outcome priorities. A well-designed health technology assessment review anticipates these variations rather than forcing a one-size-fits-all synthesis. Firms working across jurisdictions frequently pair this work with regulatory and pharmaceutical evidence support to align the review with each agency's dossier format.
Clinical, Economic, and Humanistic Reviews
An HTA evidence package is rarely a single review. It is usually a coordinated set of reviews addressing three complementary questions, and each has its own protocol, databases, and appraisal tools.
The Clinical SLR
The clinical systematic literature review identifies the efficacy and safety evidence for the technology and its comparators. It typically prioritizes randomized controlled trials but may include real-world and observational evidence where trials are absent. This review supplies the effect estimates that feed an indirect treatment comparison (ITC) or an economic model.
The Economic SLR
The economic review captures published cost-effectiveness analyses, cost studies, and resource-use data. It informs the structure and inputs of the de novo economic model and shows a payer that existing economic evaluations have been considered. This strand is central to the market access argument because it connects clinical benefit to willingness-to-pay thresholds.
The Humanistic SLR
The humanistic review gathers health-related quality-of-life and patient-reported outcome evidence, including utility values used to calculate quality-adjusted life years. Utility estimates from this review are often the most influential input in a cost-utility model, so the search must be thorough and the extraction precise. Together these three strands constitute the broader field of health economics and outcomes research (HEOR), and our evidence synthesis services are structured to deliver them as an integrated package rather than as disconnected reviews.
Scoping the Review With PICOS
Every credible HTA review begins with a written protocol, and the analytic heart of that protocol is the PICOS framework: population, intervention, comparators, outcomes, and study design. In the HTA setting, PICOS is not an academic formality. The comparator element in particular is where submissions succeed or fail, because agencies such as G-BA and NICE will reject an evidence base that omits a therapy they consider standard of care.
Scoping decisions are made deliberately and documented so they can be defended. The population is defined to match the anticipated label and the reimbursement indication. The comparators are chosen to reflect real clinical practice in each target market, which may mean different comparator sets for different agencies. The outcomes are pre-specified and ranked, distinguishing the endpoints that drive value from secondary measures. The study-design filter determines whether the review is restricted to trials or extends to observational and real-world data. A disciplined PICOS specification also defines whether the project is a full review or a targeted review, a distinction covered later. Getting the scope right at the protocol stage prevents the costly rework that follows when an agency challenges the decision problem.
Searching Clinical and Economic Databases
An HTA search must be comprehensive and reproducible, and it spans more sources than a typical academic review. Bibliographic databases such as MEDLINE, Embase, and the Cochrane Library form the clinical core. Economic and humanistic strands add specialist sources, historically including databases such as NHS EED and HEED, alongside cost and utility repositories. Crucially, the search extends into grey literature: HTA agency websites, regulatory documents, clinical trial registries, and conference proceedings, because pivotal comparator data are often unpublished or reported only at congresses.
Search strategies are documented to the exact syntax used in each database, with dates, filters, and hit counts recorded so an agency reviewer can reproduce them. This transparency is not optional; several HTA bodies re-run searches during their critique and will flag any strategy they cannot replicate. The search is deliberately sensitive rather than precise, accepting a large volume of records to minimize the risk of missing a relevant study. That sensitivity makes the downstream screening workload substantial and explains why efficient screening matters in a deadline-driven project.
Screening and Data Extraction
Screening proceeds in two stages: a title-and-abstract pass followed by a full-text assessment against the pre-specified eligibility criteria. Best practice uses two independent reviewers with a documented reconciliation process for disagreements, because a payer will question a single-reviewer decision. Every exclusion at the full-text stage is recorded with a reason, and those reasons populate the flow diagram that accompanies the final report. Teams often generate that diagram with a tool such as our PRISMA flow diagram generator to keep the record accurate as counts change through the project.
Data extraction then captures a structured set of fields from each included study: design, population characteristics, interventions and comparators, sample sizes, outcome definitions, effect estimates, and funding sources. For an HTA review the extraction template is broader than an academic one because it must also feed downstream analyses, so it captures the numerical detail an indirect treatment comparison or an economic model will need. Extraction is double-checked against source documents, since a single transcription error in an effect size can distort a whole cost-effectiveness result. Discipline at this stage is what makes the later synthesis defensible under agency scrutiny.
Quality Appraisal: AMSTAR 2 and Risk of Bias
Appraisal in an HTA review operates on two levels. When existing systematic reviews are included as evidence, their methodological quality is assessed with AMSTAR 2, a validated instrument that rates a review across sixteen items and flags critical weaknesses such as an absent protocol, an incomplete search, or a failure to account for risk of bias in the included studies. AMSTAR 2 helps a team decide how much confidence to place in previously published reviews before relying on them.
At the level of individual studies, formal risk of bias assessment applies the tool appropriate to the design: Cochrane RoB 2 for randomized trials and ROBINS-I for non-randomized studies. These assessments matter in the HTA setting because bias in the underlying trials propagates directly into any network meta-analysis and into the economic model. An agency reviewer will examine both the appraisal method and its conclusions, so the ratings must be transparent and reproducible. Rigorous appraisal is the mechanism that lets a payer trust the numbers presented, and it distinguishes a submission-grade review from a superficial literature scan.
When Head-to-Head Trials Are Missing: ITC and NMA
One of the defining challenges of market access evidence is that direct head-to-head trials between a new therapy and every relevant comparator rarely exist. A trial may compare a drug against placebo or against one active comparator, yet a payer needs to know how it performs against the full range of alternatives in clinical use. This is where indirect methods become essential.
An indirect treatment comparison (ITC) estimates the relative effect of two treatments never compared directly, using their respective trials against a common comparator. A simple anchored comparison such as the Bucher method works when a shared comparator exists, while population-adjusted approaches such as matching-adjusted indirect comparison address differences between trial populations when individual patient data are available for one side. When multiple treatments and multiple trials form a connected evidence network, a network meta-analysis (NMA) synthesizes the whole set simultaneously, producing coherent relative-effect estimates and a ranking of therapies. These methods carry strict assumptions, particularly the assumption that trials are similar enough in population and design to be combined, and violations must be examined and reported honestly. Because the statistical modeling here is demanding and heavily scrutinized by HTA agencies, many teams commission dedicated network meta-analysis and quantitative synthesis support to ensure the analysis withstands agency critique. The credibility of a reimbursement case often rests on how carefully these indirect comparisons are justified.
Reporting to PRISMA Standards
An HTA review is reported to PRISMA standards so that its methods and results are transparent end to end. The PRISMA flow diagram documents the number of records identified, screened, excluded, and finally included, giving an agency a clear audit trail from search to synthesis. The reporting checklist ensures that the protocol, eligibility criteria, search strategy, appraisal methods, and synthesis approach are all described in enough detail to be reproduced.
For HTA specifically, reporting goes beyond the standard checklist. Submissions typically include the full search syntax for every database, a complete list of excluded full-text studies with reasons, the appraisal ratings for each included study, and a clear account of any indirect comparison methods and their assumptions. This documentation lets a reimbursement committee verify the evidence independently rather than take conclusions on trust. In this field, transparent reporting is a prerequisite for a submission to be accepted for review at all.
How an SLR Feeds a Global Value Dossier or AMCP Dossier
The systematic review is rarely the final deliverable. Its outputs flow into the strategic documents that carry a product's value story to decision-makers. A global value dossier is a master reference that consolidates the clinical, economic, and humanistic evidence into a single coherent narrative, which local affiliates then adapt into country-specific HTA submissions. The SLR supplies the underlying evidence tables, the comparator effect estimates, and the appraisal that give the dossier its authority.
In the United States, an AMCP dossier follows the format of the Academy of Managed Care Pharmacy and presents evidence to formulary decision-makers at health plans and pharmacy benefit managers. Here too, the SLR provides the evidence base, and the indirect comparisons feed the value and budget-impact arguments. Because these dossiers are living documents that are updated as new trials read out, the underlying reviews are often designed to be refreshed efficiently. The tighter the link between the review protocol and the eventual dossier structure, the less rework a team faces when evidence evolves. When a product is ready to move from evidence generation to submission, our HTA and market access review service connects the review directly to the dossier so that nothing is lost in translation, and teams can request a scoped quote once the decision problem is defined.
Targeted Versus Full Reviews
Not every decision requires an exhaustive review, and choosing the right scale is a strategic decision in itself. A full systematic review applies the complete, comprehensive process across all relevant databases and is the standard expectation for a major national HTA submission where the evidence base must be demonstrably complete. It is resource intensive and time consuming, but it is defensible against the most rigorous agency critique.
A targeted review, sometimes called a focused or pragmatic review, narrows one or more elements of the process to answer a specific question faster. It might restrict the databases searched, limit the date range, or focus on a single comparator or outcome. Targeted reviews suit early strategic decisions, landscape assessments, or updating a section of an existing evidence base, but they carry a transparency obligation: any narrowing of scope must be stated explicitly so readers understand the limits of the conclusions. The skill lies in matching the review type to the decision at hand, investing full rigor where a payer demands it and moving efficiently where a lighter approach is defensible. That judgment, applied by an experienced PhD methodologist, often separates an evidence program that meets its deadlines from one that does not.
Bringing It Together
A systematic literature review for health technology assessment reorients the machinery of academic evidence synthesis toward the needs of payers and reimbursement agencies. It is defined by precise PICOS scoping, comprehensive clinical and economic searching, rigorous appraisal with AMSTAR 2 and formal risk of bias tools, principled use of indirect treatment comparison and network meta-analysis where direct trials are absent, and transparent PRISMA reporting that stands up to agency scrutiny. Done well, it becomes the evidentiary spine of a global value dossier or an AMCP dossier and gives a product its best chance of a favorable market access outcome, without promising a result that only the agency can decide.
A rigorous, doctoral-level guide to conducting a meta-analysis: defining the question, extracting effect sizes and their variances, choosing a between-study variance estimator, pooling, and diagnosing heterogeneity and bias.
To hire a statistician, you brief a qualified expert on your research question and data, and they choose the right analysis, run it in your required software, and explain every result in writing. Research Gold pairs you with a PhD statistician who handles study design, data cleaning, the analysis itself, and a defensible written interpretation, fully online, by the project or the hour, across the health, social, and physical sciences.
Meta-analysis in psychology pools the effect sizes from many studies into one reliable result. Learn the definition, real examples, and how researchers run one.
